news

CUPERTINO, Calif., Nov. 4, 2013 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the third quarter of 2013. Total revenues were $3.0 million for the three months ended September 30, 2013 as compared to $3.8 million for the three months ended September 30, 2012.  Net loss for the three months ended September […]

CUPERTINO, Calif., Oct. 28, 2013 /PRNewswire/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) third quarter 2013 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, November 4, 2013 at 4:30 pm Eastern Time (1:30 pm Pacific Time). (Logo:  http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) A

CUPERTINO, Calif., Oct. 22, 2013 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that Pfizer Inc. (NYSE: PFE) has stated that, having achieved technical milestones related to manufacturing, they will continue the development program for REMOXY® (oxycodone) Extended-Release Capsules CII. Following guidance received from the U.S. Food and Drug Administration (FDA) earlier this year, Pfizer announced

Jay Shepard to join the Board effective September 26, 2013 Michael Casey to retire from the Board effective December 31, 2013 CUPERTINO, Calif., Sept. 27, 2013 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that Jay Shepard will join its Board of Directors effective September 26, 2013.  Separately, Michael Casey has made the decision to

CUPERTINO, Calif., Sept. 3, 2013 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at three upcoming healthcare conferences. (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) James E. Brown, President and CEO, will present at the Rodman and Renshaw Conference on Monday, September 9 at 10:00 a.m. Eastern time.  The conference is being held at the

CUPERTINO, Calif., Aug. 5, 2013 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the second quarter of 2013. Total revenues were $3.9 million for the three months ended June 30, 2013 as compared to $4.8 million for the three months ended June 30, 2012.  Net loss for the three months ended June

CUPERTINO, Calif., Aug. 1, 2013 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it and its collaborator Orient PHARMA Co., Ltd., a diversified multinational pharmaceutical, healthcare and consumer products company with headquarters in Taiwan, have selected a lead formulation for the lead program in DURECT’s ORADUR-ADHD program, ORADUR-Methylphenidate.  This lead formulation was chosen based

CUPERTINO, Calif., July 26, 2013 /PRNewswire/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) second quarter 2013 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, August 5, 2013 at 4:30 pm Eastern Time (1:30 pm Pacific Time). (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) A

CUPERTINO, Calif., June 20, 2013 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that the New Drug Application (NDA) for the investigational product POSIDUR (SABER-Bupivacaine) has been accepted by the U.S. Food and Drug Administration (FDA) indicating that the application is sufficiently complete to permit a substantive review. POSIDUR is a post-operative pain relief depot that

CUPERTINO, Calif., May 10, 2013 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that Pfizer has provided an update on Remoxy as part of their Form 10-Q filing.  Pfizer’s disclosure is as follows: “In 2005, King Pharmaceuticals, Inc. (King) entered into an agreement with Pain Therapeutics, Inc. (PT) to develop and commercialize Remoxy.  In August